id	keyword
dpc-1881	melanoma
dpc-1881	patients
dpc-1881	ipilimumab
dpc-1881	months
dpc-1881	nivolumab
dpc-1881	doi
dpc-1881	phase
dpc-1881	treatment
dpc-1881	pmid
dpc-1881	braf
dpc-1881	combination
dpc-1881	group
dpc-1881	pfs
dpc-1881	survival
dpc-1881	median